Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
3 healthcare companies for a blue-chip retirement
⏸️ Investing
4 stocks to benefit from a falling Aussie dollar
⏸️ Investing
3 golden Warren Buffett rules we don't hear enough
⏸️ Investing
Meet the 4 best healthcare stocks your money can buy
⏸️ Investing
Do you have these 6 rising stars in your portfolio?
⏸️ Investing
Do you own these top stocks from reporting season?
⏸️ Investing
3 mid-cap heroes that made investors rich in August
⏸️ Investing
3 reasons to stick with your Cochlear Limited shares
⏸️ Investing
Could it be time to buy Transurban Group, Cochlear Limited and JB Hi-Fi Limited?
⏸️ Investing
These 3 shares are at 52-week highs: Is there more to come?
⏸️ Investing
Today's the reason why Buy and Hold works best
⏸️ Investing
What do Cochlear Limited's full-year results mean for its outlook?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
